Radiaction Medical Ltd. Secures Additional Patents in US and Japan – En-Route to Commercialization of its Radiation Shielding Technology

Radiaction Medical Ltd. (“Radication”), a medical device company, announced today that it was granted additional patents in the US and Japan, protecting key technological developments of its radiation shielding device.

Radiaction Medical, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures. Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.  The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.

Tested in a real-life clinical environments, the system demonstrated an entire room scattered radiation reduction performance of 91.2% in IC procedures and 93.3% in EP procedures. These rates are on par with the protection provided to the body’s core by lead aprons. Importantly, Radiaction Medical is protecting heads, arms, long bones and feet which are outside of the lead apron and are exposed and subjected to harmful cumulative radiation damage. This clinical experience also demonstrated high physician satisfaction with the integration into the clinical workflow.

Radiaction Medical has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device. The on-going advancements include various automation features, that allow smooth integration into clinical workflow and superior shielding of medical staff.

“We are pleased by the ongoing validation of our radiation shielding technology’s differentiation,” said Mr. Jonathan Yifat, CEO of Radiaction Medical. “As we are nearing commercialization, these patents strengthen our strategic IP assets and further our mission to provide a safe environment for healthcare teams in the interventional suite,” added Mr. Yifat.

In addition, the company successfully gained CE mark under the MDR with Emergo, paving the way for European initial installations at selected sites.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy